Drug intelligence / Profile preview

Cofsils

Development stage
Unknown
Lead developer
Cipla Health
Modality
Small Molecules
Administration
Oral, Buccal, Topical
01

Overview

Cofsils is a prominent consumer healthcare brand developed by Cipla Health, specializing in over-the-counter (OTC) treatments for sore throat and cough. The brand's most recognized product is the Cofsils Lozenge, which typically contains a combination of two antiseptic agents: 2,4-dichlorobenzyl alcohol and amylmetacresol. These components provide rapid relief by targeting bacteria and viruses in the oral cavity and throat, while also exerting a mild local anesthetic effect. Beyond lozenges, the Cofsils portfolio includes specialized cough syrups such as Cofsils DX (containing dextromethorphan and chlorpheniramine for dry cough) and Cofsils Wet Cough (containing expectorants and bronchodilators), as well as Cofsils Gargle (povidone-iodine) and Cofsils Naturals (herbal ingredients). It is widely distributed in the Indian market for the symptomatic management of upper respiratory tract infections.

Brand names
CofsilsCofsils DXCofsils NaturalsCofsils Panacea
Other names
2,4-dichlorobenzyl alcohol + amylmetacresol
02

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRB2 (β2)NaV (Voltage-gated sodium channels)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Cofsils.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cofsils.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call